XML 53 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue - Composition of Total Revenue by Product and U.S versus Rest of World (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Disaggregation Of Revenue [Line Items]        
Total revenue $ 216.8 $ 187.9 [1] $ 419.1 $ 366.7 [1]
U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 205.8 177.3 397.5 346.7
RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 11.0 10.6 21.6 20.0
Molecular Diagnostic - Hereditary Cancer Testing [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 126.7 122.2 243.1 239.2
Molecular Diagnostic - Hereditary Cancer Testing [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 123.4 119.6 237.0 234.2
Molecular Diagnostic - Hereditary Cancer Testing [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 3.3 2.6 6.1 5.0
Molecular Diagnostic - GeneSight [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 24.0 31.7 53.2 60.5
Molecular Diagnostic - GeneSight [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 24.0 31.7 53.2 60.5
Molecular Diagnostic - Prenatal [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 31.2   49.3  
Molecular Diagnostic - Prenatal [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 31.2   49.3  
Molecular Diagnostic- VectraDA [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 11.8 11.1 24.8 25.1
Molecular Diagnostic- VectraDA [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 11.8 11.1 24.8 25.1
Molecular Diagnostic - Prolaris [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 6.1 4.2 12.3 8.1
Molecular Diagnostic - Prolaris [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 6.1 4.2 12.3 8.1
Molecular Diagnostic - EndoPredict [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 2.2 2.0 4.6 3.8
Molecular Diagnostic - EndoPredict [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 0.4 0.1 0.7 0.1
Molecular Diagnostic - EndoPredict [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 1.8 1.9 3.9 3.7
Molecular Diagnostic - Other [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 1.0 1.9 4.7 3.8
Molecular Diagnostic - Other [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 0.7 1.7 4.4 3.5
Molecular Diagnostic - Other [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 0.3 0.2 0.3 0.3
Molecular Diagnostic Testing [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 203.0 173.1 [1] 392.0 340.5 [1]
Molecular Diagnostic Testing [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 197.6 168.4 381.7 331.5
Molecular Diagnostic Testing [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 5.4 4.7 10.3 9.0
Pharmaceutical and Clinical Services [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 13.8 14.8 [1] 27.1 26.2 [1]
Pharmaceutical and Clinical Services [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 8.2 8.9 15.8 15.2
Pharmaceutical and Clinical Services [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue $ 5.6 $ 5.9 $ 11.3 $ 11.0
[1] Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements contained in Part I, Item 1 of this report for additional information.